At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 81 enrolled
Drug / intervention
0.003% AR-15512 ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3b Open-Label Study Designed to Evaluate Tear Production Stimulated by 0.003% AR-15512
In Brief
A Phase 3 clinical trial evaluating 0.003% AR-15512 ophthalmic solution for Dry Eye Disease. Completed, enrolled 81 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate tear production following acute administration of AR-15512 ophthalmic solution 0.003% (0.003% AR-15512) in subjects with dry eye disease (DED).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Disease
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20252026
First PostedAug 2024
Enrollment StartOct 2024
Primary CompletionJan 2025
TodayJul 2026
First PostedAug 9, 2024
Enrollment StartOct 15, 2024
Primary CompletionJan 30, 2025
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 1.9 years ago
Interventions
0.003% AR-15512 ophthalmic solutiondrug
Investigational ophthalmic solution administered via topical instillation